MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Synucleinopathies"

  • 2017 International Congress

    Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease

    E. Tsika, E. Gabellieri, A. Davranche, C. Boudou, M. Ravache, L. Grasso, S. Nampally, H. Haddouk, J. Wettstein, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

    Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…
  • 2017 International Congress

    Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease

    J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen (Houston, TX, USA)

    Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…
  • 2017 International Congress

    The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

    M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

    Objective: We aim to describe the molecular pathways at the crossroad of etiology and susceptibility in PD, focusing on Rin, coded by the recently associated…
  • 2017 International Congress

    Brain insulin resistance in Parkinson’s disease

    F. Bassil, M.-H. Canron, N. Dutheil, A. Vital, E. Bezard, P.-O. Fernagut, W. Meissner (Bordeaux, France)

    Objective: To test the hypothesis that brain insulin resistance (i.e. decreased insulin/insulin like growth factor (IGF)-1 signaling) occurs in the substantia nigra pars compacta (SNc)…
  • 2016 International Congress

    A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)

    S. Gandhi, M.H. Horrocks, S.F. Lee, N.W. Wood, D. Klenerman (London, United Kingdom)

    Objective: (1) To develop an ultra-sensitive method to visualize single amyloid oligomers and (2) to compare the oligomer load in CSF from patients with PD…
  • 2016 International Congress

    Targeting TLR4 for disease modification in multiple system atrophy: Experimental evidence

    S. Venezia, V. Refolo, N. Stefanova (Innsbruck, Austria)

    Objective: To assess the efficacy of toll-like receptor 4(TLR4) agonists to ameliorate the functional and neuropathological phenotype of a transgenic mouse model of multiple system…
  • 2016 International Congress

    Detailed proteomic analysis of early PD brain highlights altered expression of mitochondrial proteins as an important event in sporadic PD

    S. Gandhi, C.E. Murray, W.E. Heywood, J.L. Holton, K. Mills, T. Revesz (London, United Kingdom)

    Objective: To uncover early pathogenic events occurring prior to neuronal loss and Lewy body formation in human PD brain. Background: In PD, pathological changes spread…
  • 2016 International Congress

    Progression of microglial activation and neuroinflammatory responses in a transgenic mouse model of multiple system atrophy

    V. Refolo, S. Venezia, G.K. Wenning, M. Romero-Ramos, N. Stefanova (Innsbruck, Austria)

    Objective: Our aim was to characterize the progression of microglial activation during disease progression in a transgenic mouse model of multiple system atrophy (MSA). Background:…
  • 2016 International Congress

    ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways

    T. Hasegawa, R. Oshima, K. Tamai, N. Sugeno, A. Kikuchi, J. Kobayashi, S. Yoshida, A. Takeda, N. Tanaka, M. Aoki (Sendai, Japan)

    Objective: Endosomal sorting required for transport (ESCRT) orchestrates endo-lysosomal soring of ubiquitinated proteins, multivesicular body formation. The aim of this study is to elucidate the…
  • 2016 International Congress

    Low cerebrospinal fluid 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol levels are biomarkers of Parkinsonian disorders, including PSP

    A. Stefani, C. Holmes, E. Olivola, Y. Sharabi, D. Goldstein (Rome, Italy)

    Objective: To assess whether Progressive Sopranuclear Palsy (PSP) patients show, in CSF an alteration of catecholamine metabolites. Background: It was reported previously that, consistent with…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley